Passion for Innovation. Compassion for Patients.™
Daiichi Sankyo Europe GmbHEuropean News
MD Anderson and Daiichi Sankyo Enter Research Collaboration to Accelerate Development of Acute Myeloid Leukemia Therapies
Houston, Tokyo and Basking Ridge, N.J. - (September 14, 2017) - The University of Texas MD Anderson Cancer Center and Daiichi Sankyo Company, Limited...
Daiichi Sankyo Showcases New Insights on Multiple Oncology Compounds at the European Society for Medical Oncology (ESMO) 2017 Congress
• Presentation to highlight DS-8201 data in subgroup of patients with HER2-expressing solid tumors including colon cancer, non-small cell lung cancer...
Bristol-Myers Squibb and Daiichi Sankyo Announce Research Collaboration to Evaluate Opdivo® (nivolumab) and DS-8201 in HER2-Expressing Breast and Bladder Cancers
(NEW YORK and TOKYO – August 28, 2017) - Bristol-Myers Squibb Company (NYSE: BMY) and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo)...
Daiichi Sankyo Enters Worldwide Licensing Agreement with Boston Pharmaceuticals for a Highly Selective RET Inhibitor for Solid Tumors
Tokyo, Japan, Basking Ridge, NJ, and Cambridge, MA – (August 28, 2017) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Boston...
Zymeworks and Daiichi Sankyo Announce Successful Achievement of a Research Milestone in Bispecific Antibody Collaboration
Vancouver, Canada, Tokyo, Japan and Basking Ridge, NJ - (July 18, 2017) - Zymeworks Inc. ("Zymeworks"), a clinical-stage biopharmaceutical company...
Daiichi Sankyo, Max Planck Innovation and Lead Discovery Center Announce Cancer Research Collaboration
Tokyo, Japan, Basking Ridge, NJ and Dortmund, Germany - (July 11, 2017) - Daiichi Sankyo Co., Limited (hereafter, Daiichi Sankyo), Max Planck...
Daiichi Sankyo Cancer Enterprise Pipeline Data Showing Swift Progress in Precision Medicine for Breast Cancer to be Presented at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
- Antibody Drug Conjugate (ADC) Franchise presentations include clinical data on smart chemotherapy DS-8201 in HER2-expressing tumors including T-DM1...
Daiichi Sankyo Announces 15 Billion Yen Manufacturing Investment to Support Acceleration of Antibody Drug Conjugate Portfolio
Intended for US and EU Medical Media Only
- Significant investment in antibody drug conjugate (ADC) manufacturing capabilities will improve research...
Daiichi Sankyo Cancer Enterprise Showcases New Data on Multiple Compounds at American Association for Cancer Research 2017 Annual Meeting
Intended for US and EU Medical Media Only
Daiichi Sankyo Cancer Enterprise Showcases New Data on Multiple Compounds at American Association for...
World Stroke Day 2016: Research reveals delayed diagnosis leaves atrial fibrillation patients at major stroke risk
• Atrial fibrillation (AF) increases the risk of a severe stroke [1] however almost half of patients are unaware of the risk [2]
• The AFfect survey...
More Stories
